Treatment of proton pump inhibitor-resistant patients with gastroesophageal reflux disease.
Kinoshita
Yoshikazu
Y
Kazumori
Hideaki
H
Ishihara
Shunji
S
D000818:Animals; D054360:Chemokine CXCL1; D019743:Chemokines, CXC / Q000096:biosynthesis; D051546:Cyclooxygenase 2 / Q000096:biosynthesis / Q000187:drug effects; D004383:Duodenogastric Reflux / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004941:Esophagitis / Q000188:drug therapy* / Q000201:enzymology* / Q000209:etiology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000187:drug effects; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000494:pharmacology / Q000627:therapeutic use; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D044463:Receptor, PAR-1 / Q000096:biosynthesis / Q000187:drug effects; D044464:Receptor, PAR-2 / Q000096:biosynthesis / Q000187:drug effects; D014357:Trypsin / Q000187:drug effects* / Q000378:metabolism
D054360:Chemokine CXCL1; D019743:Chemokines, CXC; C513297:Cxcl1 protein, rat; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D012333:RNA, Messenger; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; C077442:trypsin, pancreatic, type V-S; D052247:Nitric Oxide Synthase Type II; D051546:Cyclooxygenase 2; D014357:Trypsin